title: Clinical evidence of the relationship between aspirin and breast cancer risk (review).
abstract: In the search for new therapeutic alternatives against cancer, either as a preventive treatment or for advanced stages, it is common to appeal to well-known drugs used for the treatment of other diseases that may interfere with the metabolic pathways involved in carcinogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) display anticancer activity through the inhibition of the COX-2 enzyme, triggering processes such as apoptosis, a reduction in proliferation and inhibition of carcinogenesis. Breast cancer is a neoplasm with the highest incidence and mortality rate among young women worldwide. Epidemiologic data have shown that drugs such as NSAIDs, particularly aspirin, reduce the relative risk of breast cancer. However, in the subgroup of responsive patients, dose, time and frequency of use have not yet been established. Here, we review the reports published during the last 10 years regarding the relationship between breast cancer and aspirin.
authors.affiliation: Unidad de Bioquímica, Instituto Nacional de Ciencias Médicas y Nutrición 'Salvador Zubirán', Tlalpan 14000, Mexico, D.F., Mexico.
authors.forename: Nadia J
authors.initials: NJ
authors.lastname: Jacobo-Herrera
authors.affiliation: Unidad de Biomedicina FES-Iztacala, Universidad Nacional Autónoma de México UNAM, Tlalnepantla 54090, Mexico.
authors.forename: Carlos
authors.initials: C
authors.lastname: Pérez-Plasencia
authors.affiliation: Unidad de Bioquímica, Instituto Nacional de Ciencias Médicas y Nutrición 'Salvador Zubirán', Tlalpan 14000, Mexico, D.F., Mexico.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Camacho-Zavala
authors.affiliation: Unidad de Biomedicina FES-Iztacala, Universidad Nacional Autónoma de México UNAM, Tlalnepantla 54090, Mexico.
authors.forename: Gabriela Figueroa
authors.initials: GF
authors.lastname: González
authors.affiliation: Laboratorio de Oncogenómica, Instituto Nacional de Cancerología, Tlalpan 14080, Mexico, D.F., Mexico.
authors.forename: Eduardo López
authors.initials: EL
authors.lastname: Urrutia
authors.affiliation: Unidad de Biomedicina FES-Iztacala, Universidad Nacional Autónoma de México UNAM, Tlalnepantla 54090, Mexico.
authors.forename: Verónica
authors.initials: V
authors.lastname: García-Castillo
authors.affiliation: Unidad de Bioquímica, Instituto Nacional de Ciencias Médicas y Nutrición 'Salvador Zubirán', Tlalpan 14000, Mexico, D.F., Mexico.
authors.forename: Alejandro
authors.initials: A
authors.lastname: Zentella-Dehesa
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000627:therapeutic use*; D001241:Aspirin / Q000008:administration & dosage* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D051546:Cyclooxygenase 2 / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D039781:PubMed
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D001241:Aspirin